SCHEMBL2937142

SCHEMBL2937142

CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)N(C(=O)OC(C)(C)C)C(=O)c1ccc(CCS(=O)(=O)O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
NCOR2 Q9Y618 1/20 0.37
GPR119 Q8TDV5 3/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA12 O43570 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
ESRRG P62508 1/20 0.35
RCE1 Q9Y256 1/20 0.34
S1PR1 P21453 2/20 0.33
S1PR2 O95136 1/20 0.33
S1PR3 Q99500 1/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
CYP4A11 Q02928 1/20 0.33
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2937645 0.80 GPR119 (0.47) HDAC3HDAC1HDAC2NCOR2GPR119
SCHEMBL2935519 0.79 HDAC1 (0.40) HDAC3HDAC1HDAC2NCOR2GPR119
SCHEMBL9908273 0.79 HDAC3 (0.41) HDAC3HDAC1HDAC2NCOR2GPR119
SCHEMBL21997299 0.78 HTR2C (0.38) HDAC3HDAC1HDAC2NCOR2CA2
SCHEMBL28755156 0.76 RCE1 (0.42) HDAC3HDAC1RCE1ESR1ESR2
SCHEMBL2028232 0.71 L3MBTL1 (0.52) HDAC1CA1CA2CA12CA14
SCHEMBL2028233 0.69 S1PR1 (0.39) CA1CA2CA12CA9CA14
SCHEMBL28989018 0.69 ESRRG (0.52) HDAC3HDAC1HDAC2NCOR2GPR119
SCHEMBL2937753 0.69 HDAC3 (0.42) HDAC3HDAC1HDAC2NCOR2SMN1; SMN2
SCHEMBL27449196 0.67 CYP4A11 (0.41) HDAC1CA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8197793-B2 Methods of radiofluorination of biologically active vectors GE HEALTHCARE AS (NO) 2012-06-12 US disclosed
EP-1601384-B1 METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS GE HEALTHCARE AS (NO) 2010-09-22 EP disclosed
US-20100068139-A1 Methods of radiofluorination of biologically active vectors GE HEALTHCARE AS (NO) 2010-03-18 US disclosed
EP-1601384-A1 METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS Amersham Health AS (NO) 2005-12-07 EP disclosed
WO-2004080492-A1 METHODS OF RADIOFLUORINATION OF BIOLOGICALLY ACTIVE VECTORS AMERSHAM HEALTH AS (NO) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068139-A1 Methods of radiofluorination of biologically active vectors DOHH, VGF, HNRNPH3 HDAC3 188/4885HDAC1 368/4885HDAC2 1097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.